In short
A groundbreaking clinical trial is underway to investigate the potential of IPH6501, a new drug designed to treat patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma. This international, first-in-human study aims to evaluate the safety, tolerability, and preliminary effectiveness of IPH6501 in patients who have not responded well to previous treatments. The trial consists of two phases: a dose-finding phase and a dose expansion phase, offering hope for those battling this challenging form of cancer.
At a glance
- Study Type
- Phase 1/2, open-label, multicenter trial
- Drug
- IPH6501
- Target Condition
- Relapsed/Refractory CD20+ B-cell Non-Hodgkin Lymphoma
- Primary Objective
- Evaluate safety, tolerability, and determine recommended Phase 2 dose
- Secondary Objectives
- Investigate preliminary antitumor activity, evaluate pharmacokinetics and immunogenicity
- Study Duration
- Up to 22 months (including treatment and follow-up)
- Key Outcomes
- Safety profile, Objective Response Rate, Duration of Response, Progression Free Survival
What is IPH6501?
IPH6501 is a new drug currently being studied for the treatment of certain types of blood cancers. It's specifically designed to target CD20-expressing Non-Hodgkin Lymphoma, a group of blood cancers that affect white blood cells called lymphocytes.
What condition does IPH6501 target?
IPH6501 is being developed to treat B-Cell Non-Hodgkin Lymphoma (NHL). This is a type of cancer that starts in white blood cells called B-lymphocytes, which are an important part of the immune system. The drug is specifically designed for patients whose lymphoma has either come back after treatment (relapsed) or hasn't responded well to previous treatments (refractory).
Current Clinical Trial
IPH6501 is currently being tested in a clinical trial. This trial is described as an "international, first-in-human, multicenter, open-label Phase 1/2 study". Let's break down what this means:
- International and multicenter: The study is being conducted in multiple countries and at multiple medical centers.
- First-in-human: This is the first time the drug is being tested in human subjects.
- Open-label: Both the researchers and the patients know which treatment is being given.
- Phase 1/2: This combines the first two phases of clinical trials, which focus on safety, dosing, and early signs of effectiveness.
Objectives of the Clinical Trial
The main goals of this clinical trial are:
- To evaluate the safety profile of IPH6501
- To determine how well patients tolerate the drug
- To find the right dose for future studies (called the "recommended phase 2 dose" or RP2D)
Phases of the Clinical Trial
The trial is divided into two main phases:
Phase 1 - Dose Finding
This phase includes patients with advanced, confirmed CD20+ B-cell NHL. It has two parts:
- Dose escalation: This part aims to find the highest dose that doesn't cause unacceptable side effects (called the Maximum Tolerated Dose or MTD).
- Dose assessment: This part will determine the recommended dose for Phase 2 (RP2D).
Phase 2 - Dose Expansion
In this phase, one or more groups of patients with specific subtypes of advanced CD20+ B-cell NHL will receive the dose determined in Phase 1.
Safety and Efficacy Measures
The trial will measure several outcomes to assess both the safety and effectiveness of IPH6501:
- Safety and tolerability: This is the primary focus, monitored throughout the study period of up to 22 months.
- Objective Response Rate (ORR): This measures how many patients have a significant reduction in their cancer.
- Duration of Response (DoR): This looks at how long the positive effects of the treatment last.
- Progression Free Survival (PFS): This measures how long patients live without their cancer getting worse.
Pharmacokinetics and Immunogenicity
The study will also look at how IPH6501 behaves in the body:
- Pharmacokinetics: This includes measuring the maximum concentration of the drug in the blood (Cmax) and the total exposure over time (AUC).
- Immunogenicity: The study will check if patients develop antibodies against IPH6501, which could potentially affect its effectiveness.